Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM
J Natl Cancer Inst. 1988 80 (1): 60-3

PMID: 3257526 · DOI:10.1093/jnci/80.1.60

A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 X 10(6) U/m2/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (greater than 50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity.

MeSH Terms (12)

Adult Aged Carcinoma, Renal Cell Drug Administration Schedule Drug Evaluation Female Humans Interleukin-2 Kidney Neoplasms Male Melanoma Middle Aged

Connections (1)

This publication is referenced by other Labnodes entities: